20-valent pneumococcal conjugate vaccine (20vPnC)

BIOLOGICAL7 trials

Sponsors

Pfizer

Conditions

COVID-19Pneumococcal DiseaseSARS-CoV-2 Infection

Phase 1

A Study to Learn About the Safety and Immune Response of a New Pneumococcal Vaccine in Adults

CompletedNCT06182124

PfizerPneumococcal Disease

Start: 2023-12-20End: 2026-05-12Updated: 2026-06-10

Phase 2

A Study to Learn About How a New Pneumococcal Vaccine Works in Infants

Active, not recruitingNCT06524414

PfizerPneumococcal Disease

Start: 2024-07-25End: 2027-05-01Updated: 2026-09-03

A Study to Learn About How a New Pneumococcal Vaccine Works in Children

CompletedNCT06531538

PfizerPneumococcal Disease

Start: 2024-07-30End: 2026-02-09Updated: 2026-03-11

Phase 3

Safety and Immunogenicity Study of 20vPnC When Coadministered With a Booster Dose of BNT162b2

CompletedNCT04887948

PfizerCOVID-19, Pneumococcal Disease, SARS-CoV-2 Infection

Start: 2021-05-20End: 2021-12-08Updated: 2022-12-14

A Study to Learn About the Safety of an Expanded Pneumococcal Vaccine in Healthy Infants

RecruitingNCT07573462

PfizerPneumococcal Disease

Start: 2026-05-04End: 2028-12-30Target: 2400Updated: 2026-09-15

A Study to Learn About How a New Pneumococcal Vaccine Works in Infants.

RecruitingNCT07629440

PfizerPneumococcal Disease

Start: 2026-05-29End: 2029-06-05Target: 3230Updated: 2026-09-08

Study to Learn About Safety, Tolerability, and Immune Response of a Catch-up Pneumococcal Vaccine in Children and Adolescents

RecruitingNCT07660198

PfizerPneumococcal Disease

Start: 2026-06-15End: 2027-12-02Target: 1200Updated: 2026-08-31

Related Papers

Randomized trial to evaluate the safety, tolerability, and immunogenicity of a booster (third dose) of BNT162b2 COVID-19 vaccine coadministered with 20-valent pneumococcal conjugate vaccine in adults ≥65 years old.

2023-05-0812 citations